Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P O Livingston

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Seminars in Cancer Biology|December 1, 1995
Augmenting the immunogenicity of carbohydrate tumor antigensP O Livingston
Immunological Reviews|June 1, 1995
Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccinesP O Livingston
Annals of the New York Academy of Sciences|August 12, 1993
Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccinesP O Livingston
Current Opinion in Immunology|October 1, 1992
Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigensP O Livingston
Progress in Clinical and Biological Research|January 1, 1989
Experimental and clinical studies with active specific immunotherapyP O Livingston
Seminars in Cancer Biology|December 1, 1991
Ganglioside antigens expressed by human cancer cellsG Ritter, P O Livingston
Molecular and Chemical Neuropathology|February 1, 1994
Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal originF Helling, P O Livingston
Cancer Immunology, Immunotherapy : CII|November 14, 1997
Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plansP O Livingston, G Ragupathi
Human Immunology|November 1, 1984
Brief communication: HLA antigen frequencies in renal cell carcinomaM S Pollack, P O Livingston
Tissue Antigens|October 1, 1985
HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosisM S Pollack, P O Livingston
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Seminars in Cancer Biology|December 1, 1995
Augmenting the immunogenicity of carbohydrate tumor antigensP O Livingston
Immunological Reviews|June 1, 1995
Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccinesP O Livingston
Annals of the New York Academy of Sciences|August 12, 1993
Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccinesP O Livingston
Current Opinion in Immunology|October 1, 1992
Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigensP O Livingston
Progress in Clinical and Biological Research|January 1, 1989
Experimental and clinical studies with active specific immunotherapyP O Livingston
Seminars in Cancer Biology|December 1, 1991
Ganglioside antigens expressed by human cancer cellsG Ritter, P O Livingston
Molecular and Chemical Neuropathology|February 1, 1994
Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal originF Helling, P O Livingston
Cancer Immunology, Immunotherapy : CII|November 14, 1997
Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plansP O Livingston, G Ragupathi
Human Immunology|November 1, 1984
Brief communication: HLA antigen frequencies in renal cell carcinomaM S Pollack, P O Livingston
Tissue Antigens|October 1, 1985
HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosisM S Pollack, P O Livingston
Pageof 9